Henrijette Richter
Direktor/Vorstandsmitglied bei Asceneuron SA
Ursprung des Netzwerks ersten Grades von Henrijette Richter
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.
48
| Private Company | Investment Managers | 48 |
Public Company | Financial Conglomerates | 21 | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.
12
| Holding Company | Pharmaceuticals: Major | 12 |
Comet Therapeutics, Inc.
Comet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Comet Therapeutics, Inc. develops and commercializes treatments for patients suffering from metabolic, neurological and immunological disorders. The company was founded by Angellina Sekirnik and Enej Kuscer in 2008 and is headquartered in Cambridge, MA.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Mozart Therapeutics, Inc.
Mozart Therapeutics, Inc. BiotechnologyHealth Technology Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning.
10
| Holding Company | Biotechnology | 10 |
Muna Therapeutics ApS
Muna Therapeutics ApS Medical/Nursing ServicesHealth Services Muna Therapeutics ApS is a Danish private biopharmaceutical company that discovers and develops therapies to slow or stop neurodegenerative diseases such as Alzheimer's, frontotemporal dementia, and Parkinson's. Muna Therapeutics is based in Copenhagen, DK and was founded in 2020 by Simon Glerup and Bart de Strooper. The company focuses on identifying new medicines to preserve cognition and other brain functions and enhance resilience to these diseases. Rita Balice-Gordon has been the CEO of the company since 2020.
10
| Holding Company | Medical/Nursing Services | 10 |
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom.
9
| Holding Company | Biotechnology | 9 |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.
8
| Holding Company | Biotechnology | 8 |
Redona Therapeutics, Inc.
Redona Therapeutics, Inc. BiotechnologyHealth Technology Redona Therapeutics, Inc.operates as a biotechnology company focused on the modulation of non- RNA (ncRNA) function to treat cancer and other human diseases. It uses small molecules to modulate expression levels of oncogenes and other proteins of significance in disease. The company was founded by George Daley, Richard Gregory, Frank Slack, and Piotr Sliz and is headquartered in Watertown, MA.
7
| Holding Company | Biotechnology | 7 |
Nitrase Therapeutics, Inc.
Nitrase Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nitrase Therapeutics, Inc. develops drugs against newly discovered nitration enzyme. The firm provides disease modifying drugs for multiple additional aging-dependent diseases, such as neurodegenerative disease, heart disease and cancer. The company was founded by Irene Griswold-Prenner and is headquartered in Jackson, WY.
6
| Holding Company | Miscellaneous Commercial Services | 6 |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.
4
| Operating Division | Investment Managers | 4 |
Delinea, Inc. (United States)
Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ.
2
| Subsidiary | Biotechnology | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Henrijette Richter
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
ROCHE HOLDING AG | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Stanford University | College/University | Masters Business Admin Undergraduate Degree Doctorate Degree | |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Karolinska Institutet | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal | |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
University of California, Berkeley | College/University | Doctorate Degree Doctorate Degree | |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Chairman Chief Executive Officer Chief Executive Officer Chief Executive Officer | |
INNATE PHARMA | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
ABLYNX | Biotechnology | Director/Board Member Chairman Director/Board Member Director/Board Member | |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
University of Copenhagen | College/University | Doctorate Degree Doctorate Degree | |
ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Ecole Polytechnique | College/University | Undergraduate Degree Doctorate Degree | |
Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Investment Managers | Private Equity Investor Private Equity Investor | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
France Invest
France Invest Financial ConglomeratesFinance France Invest is a French association of investors for growth that supports private equity as a lever for business creators and managers to achieve growth. The private company is based in Paris, France and was founded by Maurice Tchenio. The association is at the heart of the economy and aims to share the value created by supporting companies in their innovation and energy transition efforts. | Financial Conglomerates | Director/Board Member Director/Board Member | |
ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member Chief Executive Officer | |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
MD Start SA
MD Start SA BiotechnologyHealth Technology MD Start SA develops medical device technology. It has collaboration between venture capital, institutional investors and industry to the development of innovative medtech ideas in Europe. The company was founded by Tim Lenihanin 2010 and is headquartered in Paris, France. | Biotechnology | Chairman Director/Board Member Chief Investment Officer | |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Chief Executive Officer | |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Drugstore Chains | Chairman Director/Board Member | |
HighLife SAS
HighLife SAS Medical SpecialtiesHealth Technology HighLife SAS develops percutaneous mitral valve replacement therapies. It offers a minimally invasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. The company was founded by Georg Börtle in 2010 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member Director/Board Member | |
Pulmocide Ltd.
Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Forendo Pharma Oy
Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Inspirna, Inc.
Inspirna, Inc. Pharmaceuticals: MajorHealth Technology Inspirna, Inc. operates as a clinical stage biopharmaceutical company which develops molecule and antibody cancer therapeutics. It provides drugs for melanoma, colorectal and triple-negative breast cancers. The firm identifies novel cancer targets using a microRNA based target discovery platform that enable the identification and validation of novel post-transcriptionally regulated targets. The company was founded by Masoud Tavazoie, Sohail Tavazoie, Shahram Seyedin-Noor and Saeed Tavazoie in 2010 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
DNA Script SAS
DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
SafeHeal SAS
SafeHeal SAS Medical SpecialtiesHealth Technology SafeHeal SAS develops anastomosis protection devices for improved patient recovery and reduced healthcare costs. The company is headquartered in Paris, France. | Medical Specialties | Chairman Director/Board Member President | |
May Health SAS
May Health SAS Miscellaneous Commercial ServicesCommercial Services May Health SAS engages in the development of device for the treatment of polycystic ovary syndrome infertility. The company was founded in September 2017 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Chairman Chairman Director/Board Member President | |
SR One Capital Management LP
SR One Capital Management LP Investment ManagersFinance SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California. | Investment Managers | Consultant / Advisor Corporate Officer/Principal Private Equity Investor | |
Noema Pharma AG
Noema Pharma AG BiotechnologyHealth Technology Noema Pharma AG is a biotechnology company, which engages in the development of orphan neurological disorder therapies. It focuses on understanding and meeting patient needs using novel therapies. The company was founded by Luigi Costa and George Garibaldi and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Director/Board Member | |
Tenpoint Therapeutics Ltd.
Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Moon Surgical SAS
Moon Surgical SAS Medical SpecialtiesHealth Technology Moon Surgical SAS is a French medical technology company that is creating a new category of robotic surgery. The company is based in Paris, France and is operated by renowned serial medical innovators and backed by leading venture capitalists. Its Maestro system enhances existing laparoscopic techniques and tools with new capabilities, benefiting the 93%% of patients who currently do not have access to minimally invasive robotic surgery. The CEO of the company is Anne Osdoit. | Medical Specialties | Director/Board Member Director/Board Member Chief Executive Officer Chief Operating Officer | |
True North Therapeutics, Inc.
True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Biotechnology | Founder Chief Executive Officer | |
Delinea, Inc.
Delinea, Inc. Information Technology ServicesTechnology Services Delinea, Inc. is a provider of privileged access management solutions for modern, hybrid enterprises. The private company is located in the US and has subsidiaries in Germany. The American company's platform extends PAM by providing authorization for all identities, granting access to an organization's most critical hybrid cloud infrastructure and sensitive data to help reduce risk, ensure compliance, and simplify security. Delinea serves customers worldwide, ranging from small businesses to the world's largest financial institutions, intelligence agencies, and critical infrastructure companies. | Information Technology Services | President Chief Executive Officer |
Statistik
International
Vereinigte Staaten | 15 |
Frankreich | 12 |
Schweden | 10 |
Deutschland | 4 |
Dänemark | 3 |
Sektoral
Health Technology | 30 |
Finance | 9 |
Consumer Services | 7 |
Commercial Services | 5 |
Retail Trade | 2 |
Operativ
Director/Board Member | 654 |
Corporate Officer/Principal | 166 |
Chairman | 149 |
Independent Dir/Board Member | 97 |
Private Equity Investor | 82 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Steven Gillis | 58 |
Gunnar Magnus Modee Persson | 51 |
Antoine Papiernik | 48 |
Viktor Drvota | 41 |
Perry Karsen | 38 |
Bo Jesper Hansen | 34 |
Gerald Heinz Möller | 29 |
Roel Bulthuis | 29 |
Catherine Moukheibir | 29 |
Deborah Harland | 27 |
Maina Bhaman | 26 |
Graziano Seghezzi | 26 |
Denis Lucquin | 26 |
Gérard Hascoët | 25 |
Karl Härfstrand | 23 |
- Börse
- Insiders
- Henrijette Richter
- Unternehmensverbindungen